ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print
Health Technology

Trans Genic Inc.

Business Summary

Trans Genic Inc. engages in the development, distribution, and licensing of genetically engineered animals and antibodies. It operates through the following segments: Contract Research Organization (CRO), Diagnostic Analysis, and Trans Genic Business Service (TGBS). The CRO segment deals with clinical trials, pharmacological tests, pharmacokinetic tests, non-clinical trials, and the production of genetically modified mice. The Diagnostic Analysis segment provides pathological diagnosis, gene analysis, and drug discovery support services for personalized medicine. The TGBS segment offers advice and support services related to the promotion of new business through mergers and acquisitions, business succession, and business revitalization. The company was founded on April 21, 1998 and is headquartered in Kumamoto, Japan.

Financial Highlights

Mar 2023 JPYUSD
Gross Profit1,994.83M14.72M
Operating income-25.15M-0.18M
Income before tax-331.80M-2.44M
Net income-409.66M-3.02M
Diluted EPS-24.32-0.17
Dividends Per Share50.03
Total Assets10,682.31M80.26M
Total liabilities4,559.79M34.26M
Total equity6,018.04M45.21M
Operating cash flow-1,430.03M-10.55M
Currency in JPYCurrency in USD

Historical Data

 Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Revenue 8,674.50M 11,046.67M 11,046.13M 12,576.56M 11,429.68M
Gross Profit 1,498.44M 1,779.72M 2,777.10M 3,835.96M 1,994.83M
Operating income 270.06M 62.70M 895.64M 1,837.30M -25.15M
Income before tax 202.87M -249.65M 695.20M 2,767.58M -331.80M
Net income 202.21M -440.71M 546.28M 1,876.33M -409.66M
EBITDA 460.51M 292.68M 1,147.11M 2,065.26M 158.36M
Diluted EPS 11.90 -25.37 31.45 109.31 -24.32
Dividends Per Share 0 0 3 6 5
Total Assets 6,475.27M 7,571.68M 8,928.90M 10,441.20M 10,682.31M
Total liabilities 1,588.53M 3,154.97M 3,892.00M 3,804.41M 4,559.79M
Total equity 4,886.74M 4,416.61M 4,916.45M 6,532.77M 6,018.04M
Operating cash flow 147.69M -20.98M 1,222.36M 1,789.20M -1,430.03M
 Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Revenue 78.22M 101.60M 104.15M 111.91M 84.34M
Gross Profit 13.51M 16.36M 26.18M 34.13M 14.72M
Operating income 2.43M 0.57M 8.44M 16.35M -0.18M
Income before tax 1.82M -2.29M 6.55M 24.62M -2.44M
Net income 1.82M -4.05M 5.15M 16.69M -3.02M
EBITDA 4.15M 2.69M 10.81M 18.37M 1.16M
Diluted EPS 0.10 -0.23 0.29 0.97 -0.17
Dividends Per Share 0 0 0.02 0.05 0.03
Total Assets 58.50M 70.13M 80.80M 86.02M 80.26M
Total liabilities 14.35M 29.22M 35.22M 31.34M 34.26M
Total equity 44.15M 40.91M 44.49M 53.82M 45.21M
Operating cash flow 1.33M -0.19M 11.52M 15.92M -10.55M

Valuation Measures

Mar 2023
Operating margin-0.22%
Profit margin-3.58%


  • Director, Manager-Finance & Accounting: Kazuo Watanabe
  • Director & Chief Technology Officer: Kenichi Yamamura
  • Director, Manager-Personnel & General Affairs: Yutaka Funabashi
  • Director & GM-Contract Research Organization: Shunichi Kitajima


  • FUJII MASAKI (1.0%)
  • Mutoh Co., Ltd. (0.9%)
  • Limousine International KK (0.8%)
  • Trans Genic Inc. (0.8%)
  • HARADA IKUO (0.8%)
  • HIRAKAWA TORU (0.4%)

Contact Details

Related Companies

  • MASC Co. Ltd.
  • Trans Genic Restricted Stock Compensation Plan
  • LunaPath LLC
  • Galax Corp.
  • Medicinal Chemistry Pharmaceutical Co. Ltd.
  • TG Business Service Inc.
  • New Drug Research Center Inc.
  • GP Biosciences Ltd. /Genetic Analysis Business/
  • HOPE Co., Ltd.
  • Primmune Inc


    Last Updated on 22 Sep, 2023

    Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

    Celebrate our next chapter
    Free access for everyone - Sep. 30

    Find out more